Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Thursday, 29 August 2019, 10:46 HKT/SGT
Share:
    

Source: Eisai
Eisai to Launch New "Etak Antimicrobial Wet Wipes" With One Week Lasting Antimicrobial Action
Alcohol-Free Wipe for Eliminating Viruses and Bacteria on Personal Belongings

TOKYO, Aug 29, 2019 - (JCN Newswire) - Eisai Co., Ltd. will launch ETAK( Antimicrobial Wet Wipes (classified as miscellaneous goods) containing long-acting antimicrobial agent ETAK on August 29, 2019 at pharmacies and drugstores countrywide.

ETAK, the main ingredient used in the product, is a long-acting antimicrobial agent developed by Professor Hiroki Nikawa of the Department of Oral Biology and Engineering at Hiroshima University's Graduate School of Biomedical and Health Sciences. An adhesive component of ETAK chemically binds the antimicrobial component to the area wiped with ETAK Antimicrobial Wet Wipes, preserving an antimicrobial effect that lasts for one week.

Eliminating virus and bacteria is a familiar and highly interested theme for consumers, especially mothers with small children.

There were many requests from mothers with small children such as "I want to use ETAK product not only inside the house but also the outside" and "I want to use ETAK product conveniently to the difficult to spray area. In response to these requests, ETAK Antimicrobial Wet Wipes has been commercialized. ETAK Antimicrobial Wet Wipes is alcohol-free so that it is easy to use for families with small children, and it can be used for elimination of viruses and bacteria on personal belongings as well as for cleaning hands and fingertips. In addition, wiping with this product can have antimicrobial barrier for personal belongings and prepare for virus and bacteria. The effect remains even if the area is wiped with water."

As the ETAK brand, containing long-acting antimicrobial agent ETAK, Eisai is marketing ETAK Antimicrobial Spray, a spray for mouth masks, which eliminates viruses and bacteria for 24 hours and ETAK Antimicrobial Spray alpha which can be used for a variety of lifestyle supplies including fabrics such as clothes and stuffed toys as well as kitchenware.

The addition of ETAK Antimicrobial Wet Wipes to the product lineup of ETAK brand will propose new options for elimination of viruses and bacteria as well as antimicrobial action, and we will contribute to further improvement of benefits of consumers who wish to keep those viruses and bacteria at bay.

*This product is not effective on all types of virus and bacteria.
*This product is not a pharmaceutical product nor a quasi-pharmaceutical product.
*ETAK is a registered trademark of CampusMedico Co., Ltd.

About Long-acting Antimicrobial Agent ETAK

ETAK was developed by Professor Hiroki Nikawa of the Department of Oral Biology and Engineering at Hiroshima University's Graduate School of Biomedical and Health Sciences. It is a patented long-acting antimicrobial agent (patent number: 4830075) that combines quaternary ammonium salts, which are also included in hand sanitizers and oral cleansing agents used by dentists, with a silane analogue, an immobilizing agent that functions as an adhesive. ETAK chemically binds the antimicrobial component to the spray area, thereby preserving the antimicrobial effect on the surface of the target object.


Contact:
Public Relations Department
Eisai Co., Ltd. 
+81-(0)3-3817-5120


Topic: Press release summary
Source: Eisai

Sectors: BioTech
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2025 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.



Eisai
Feb 20, 2025 12:29 HKT/SGT
Eisai Selected for "Human Capital Leaders 2024" and "Human Capital Management Gold Quality" for Second Consecutive Year, as a Company Committed to Excellent Management and Disclosure of Human Capital Initiatives
Feb 14, 2025 11:09 HKT/SGT
Development of Prediction Model for Brain Amyloid-Beta Accumulation for Early Screening of Alzheimer's Disease
Feb 3, 2025 16:23 HKT/SGT
Eisai to Provide Guidance on Reducing the Risk of Cognitive Decline and Nutrition, and Development Guidelines for Home Delivery Meals/Meal Kits to Food-Related Companies
Jan 28, 2025 08:46 HKT/SGT
FDA Approves LEQEMBI (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease
Jan 22, 2025 16:18 HKT/SGT
Eisai Listed as a Global 100 Most Sustainable Corporation for The Ninth Time Highest Ranked Global Pharmaceutical Company
Jan 15, 2025 09:03 HKT/SGT
FDA Accepts LEQEMBI (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease
Jan 7, 2025 08:14 HKT/SGT
Elucidation of part of the Mechanism by which Lecanemab Slows the Progression of Alzheimer's Disease
Dec 23, 2024 16:22 HKT/SGT
Fujirebio and Eisai Enter into Memorandum of Understanding for Joint Research and Social Implementation of Blood-based Biomarkers in the Field of Neurodegenerative Diseases
Dec 11, 2024 13:45 HKT/SGT
Eisai's "URECE(R)" (Dotinurad) Approved in China for Gout Patients with Hyperuricemia
Dec 5, 2024 10:22 HKT/SGT
"LEQEMBI" (Lecanemab) Approved for the Treatment of Early Alzheimer's Disease in Mexico
More news >>
 News Alerts
Copyright © 2025 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: